2022 Revenues ($USD) : $1,138,988,000
2022 R&D spend : $92,626,000
2022 Number of Employees : 2,900
Fiscal Year End : 12/31/2021
Company CEO : Chris Barry, CEO

NuVasive officials expect orthopedic technology to drive the company’s revenue growth this year. However, the spine surgery tech company reduced its EPS guidance in early August amid the macroeconomic pressures that many device companies presently face. Early this year, NuVasive announced that its Attrax Putty had received FDA 510(k) clearance for expanded indications in thoracolumbar interbody spine surgery. NuVasive officials say the Attrax Putty is the first synthetic bone graft with U.S. FDA indications for thoracolumbar interbody fusion. The company also describes Attrax as a relatively inexpensive biologic option. The company in July released some positive data around Attrax and Modulus XLIF, a porous titanium interbody implant, when it came to lateral lumbar interbody fusions. –CN